Immunai, Inc.
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology[1] |
| Founded 📆 | 2018[2] |
| Founder 👔 | |
| Headquarters 🏙️ | , , United States |
Areas served 🗺️ | Worldwide |
Key people | Luis Voloch, Noam Solomon,[4] Ansuman Satpathy, Danny Wells[5] |
| Members | |
Number of employees | 120[6] |
| 🌐 Website | immunai |
| 📇 Address | |
| 📞 telephone | |
Immunai is a New York-based biotechnology company that maps and reprograms immune-system functions using single-cell immunomics and machine learning.[7][8][9][10] Immunai is best known for its development of the world’s largest database of clinically annotated single-cell immune data, termed “AMICA” (the Annotated Multiomic Immune Cell Atlas).[11]
History[edit]
Immunai was founded in 2018 by Luis Voloch, Noam Solomon, Ansuman Satpathy, and Danny Wells.[12][13] Prior to cofounding Immunai, Solomon finished post-doctoral work in mathematics at Harvard, with Larry Guth at MIT. Voloch was an engineer at Palantir Technologies.[14] Voloch, who also studied at MIT, was awarded “Best Thesis” in computer science.[15] The pair cofounded the company with Stanford University cancer immunology professor, Ansuman Satpathy, and Danny Wells, a member of the Parker Institute for Cancer Immunotherapy.[16]
In 2020, in partnership with Baylor College of Medicine, Immunai identified a gene in CAR-NKT-mediated antitumor activity and is purposed with identifying cell therapy candidates in solid tumors.[17][18] Later that year, Immunai helped researchers at Tel Aviv University identify a combination of COVID-19 antibodies that can serve as both medication for patients and preventive treatment for high-risk populations.[19] Including Baylor College of Medicine and Tel Aviv University, Immunai has a total of 25 academic collaborations and 30 partnerships with Fortune 100 pharmaceutical partners.[20]
In 2021, the company acquired Dropprint, a similar cell-level data developer, and Switzerland-based gene expression data company, Nebion.[21][22] Following the Nebion acquisition, Immunai appointed immunologist Jacques Banchereau as its CSO.[23]
The company is headquartered in New York, with much of its machine learning and software engineering in Tel Aviv, Israel.[20] As of 2021, the company has raised $295 million from Koch Disruptive Technologies, Viola Group, TLV Partners, ICON, 8VC, Alexandria Venture Investments, Schusterman Family Investments, the Duquesne Family Office, Catalio Capital Management, Dexcel Pharma, Piedmont, and others.[24][25]
Technology[edit]
Immunai’s technology maps the immune system at the single-cell level, using a multiomic approach that looks at the transcriptome, proteome, epigenome, and TCR/BRC information of each cell.[26] This data is used to map the human immune system.[27] The company’s technology applies machine learning to identify which targets might be most effective, and inversely, which drugs might induce toxic reactions.[8] The technology aims to predict how a patient will respond to a single or combination of potential treatments. The company’s immunological atlas, AMICA, is the largest data set for clinical immunological data. As of 2021, AMICA has mapped hundreds of millions of immune cells.[28]
References[edit]
- ↑ "Biotech mapmaker Immunai launches to chart the immune system". Xconomy. Retrieved 26 July 2022.
- ↑ "AI and Cancer: Unlocking the Immune System (with Immunai's Luis Voloch)". Harvard Business Review. Retrieved 20 April 2022.
- ↑ "U.S.-Israeli biotech startup Immunai raises $20 million". Reuters. Retrieved 22 April 2022.
- ↑ "'Developing a New Drug Is Stumbling in the Dark Without a Map. We Are Building the GPS'". Haaretz. Retrieved 16 June 2022.
- ↑ "Israel's Immunai hopes to reprogram immune system with $60m. funding". JPOST. Retrieved 13 January 2022.
- ↑ "Koch leads infusion into AI startup boasting 'largest database' of immune cells". Endpoints News. Retrieved 6 May 2022.
- ↑ "Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis". Nature. Retrieved 4 May 2022.
- ↑ 8.0 8.1 "Using machine learning, Immunai plans to map immune system". Healthcare Tech News. 14 May 2020. Retrieved 13 January 2022.
- ↑ "Immunai unveils map of human immune system". Outsourcing Pharma. Retrieved 13 January 2022.
- ↑ "Immunai announces a $215M Series B as its 'immune cell atlas' matures". TechCrunch. Retrieved 13 January 2022.
- ↑ "From Atlas to Actuary: Immunai Expands Immune Mapping with $215M in Series". Genetic Engineering News. 28 October 2021. Retrieved 13 January 2022.
- ↑ "Biotech Immunai launched out of stealth". Business Insider. Retrieved 26 July 2022.
- ↑ "Biotech startup Immunai earns unicorn status". Cacalis Tech. 27 October 2021. Retrieved 13 January 2022.
- ↑ "10 Things you Didn't Know about Noam Solomon". Money Inc. 18 February 2021. Retrieved 13 January 2022.
- ↑ "The Top 100 MIT Alumni In Technology Of 2021". MIT Alumni Spotlight. Retrieved 13 January 2022.
- ↑ "Stanford-Parker Institute Scientists Team up with Two Young Engineers in 20M AI Play with an Immunology Focus". Endpoints News. Retrieved 13 January 2022.
- ↑ "Immunai Collaborates With Baylor College of Medicine To Develop Targeted, Effective Cancer Immunotherapies". Mobile Health Times. 21 October 2020. Retrieved 13 January 2022.
- ↑ "CAR NKT cells offer a promising novel immunotherapy for solid tumors". Baylor College of Medicine News. Retrieved 13 January 2022.
- ↑ "Tel Aviv U. researchers develop antibody cocktail against COVID-19". JPOST. Retrieved 6 May 2022.
- ↑ 20.0 20.1 "Israeli-Found Firm Immunai Raises $215M For Its Drug Discovery Platform". No Camels. 28 October 2021. Retrieved 13 January 2022.
- ↑ "Immunai Acquires Dropprint Genomics". Genome Web. 25 March 2021. Retrieved 13 January 2022.
- ↑ "Immunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlas". Fierce Biotech. 25 March 2021. Retrieved 13 January 2022.
- ↑ "Immunai Acquires Swiss Bioinformatics Firm Nebion". Genome Web. 29 July 2021. Retrieved 13 January 2022.
- ↑ "Israeli biotech startup Immunai raises $215m for drug discovery platform". Times of Israel. Retrieved 13 January 2022.
- ↑ "Koch Leads Mammoth 215M Influsion into AI Startup Boasting Largest Database of Immune Cells". EndPoints. Retrieved 2 June 2022.
- ↑ "Immune Cell Profiles Reveal Cancer's Leading Indicators". Genetic Engineering News. 4 March 2021. Retrieved 13 January 2022.
- ↑ "The 10 most innovative companies in artificial intelligence of 2022". Fast Company. Retrieved 20 April 2022.
- ↑ "Mapping the immune system to improve autoimmune and cancer therapies". MIT Startup Exchange. Retrieved 13 January 2022.
This article "Immunai" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Immunai. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
